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Novelty and impact: Knowledge of pancreatic cancer (PC) risk factors and preventive factors is
incomplete. Nuts have been evaluated as a potential preventive factor for PC cancer risk in
four  epidemiologic  studies,  with  inconclusive  results.  The  authors  have  assessed  this
association in  one of  the  largest  European prospective cohorts,  the European  Prospective
Investigation into Cancer and nutrition (EPIC) study. Nut intake does not appear to play a role
in PC incidence, at least not at the levels of consumption observed in EPIC. 
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ABSTRACT:
Four epidemiologic studies have assessed the association between nut intake and pancreatic
cancer  risk  with  contradictory  results.  The  present  study  aims  to  investigate  the  relation
between nut intake (including seeds) and pancreatic ductal adenocarcinoma (PDAC) risk in the
European Prospective Investigation into Cancer and Nutrition (EPIC) study. Cox proportional
hazards models were used to estimate hazards ratio (HR) and 95% confidence intervals (95%CI)
for  nut  intake  and  PDAC risk.  Information on  intake  of  nuts  was  obtained  from the  EPIC
country-specific  dietary  questionnaires.  After  a  mean  follow-up  of  14  years,  476160
participants were eligible for the present study and included 1283 PDAC cases. No association
was observed between consumption of nuts and PDAC risk (highest intake vs non-consumers:
HR:0.89, 95%CI:0.72-1.10, P-trend:0.70). Further, no evidence for effect-measure modification
was observed when different subgroups were analyzed. Overall, in EPIC, the highest intake of
nuts was not statistically significantly associated with PDAC risk.
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INTRODUCTION
Pancreatic cancer (PC) is one of the most aggressive human cancers, and it is projected to be
the second leading cause of cancer mortality by 20301. The most frequent histological type is
pancreatic  ductal  adenocarcinoma  (PDAC),  and  accounts  for  almost  95%  of  all  exocrine
pancreatic tumors2.  PC incidence is increasing, and 5-year survival is the worst (<8%) of all
common cancers since it is usually diagnosed at late stages, and few treatment improvements
have  been  achieved  in  recent  years3.  Thus,  scientific  evidence  for  primary  prevention  is
crucial4. 
Chronic pancreatitis and long-standing diabetes are associated with higher PC risk, while family
history and genetic syndromes account for <10% of all PC cases, suggesting that environmental
and lifestyle factors play a major role in PC development5–7. Tobacco smoking, heavy alcohol
consumption and body fatness are considered lifestyle risk factors6. Red and processed meat
intakes have also been associated with PC risk, but scientific evidence is still unclear. Likewise,
inconsistent results have been reported for Helicobacter pylori, physical activity, adherence to
the  Mediterranean  Diet  (MED),  and  dietary  intakes  of  fruits,  vegetables,  magnesium,  and
folate6–8.
Nuts (comprising tree nuts and peanuts) are a food group that has largely been associated with
beneficial health effects including reduced total and cause-specific mortality, cardiovascular
disease,  hypertension,  diabetes,  insulin  resistance  and  cancer  risk9–12.  The  characteristic
nutritional composition of nuts (rich in fiber, vitamins, minerals, mono- and polyunsaturated
fatty acids, and bioactive compounds) makes them an ideal food group to be studied as a
preventive factor for PC10,13. 
One  prospective  epidemiologic  study  from  the  United  States  (US)  found  evidence  for  an
inverse association between nut intake and PC risk in women14, whereas one case-control and
one prospective cohort study, both from the Netherlands, observed no statistically significant
associations15,16. A third prospective cohort study from Iran also found no clear association 17.
The purpose of the present study was to investigate the relation between the consumption of
nuts and seeds and PDAC risk accounting for dietary and lifestyle factors in one of the largest
prospective cohort studies of nutrition and chronic diseases.
METHODS
Study population
The European Prospective Investigation into Cancer and Nutrition (EPIC) is a multicenter study
that started between 1992-1998 and comprises 23 research centers in 10 European countries.
The study was approved by the IARC ethical review boards and/or all local ethics committees.
The design and methodology of the EPIC study has been published elsewhere18. 
Of the 521324 participants, a total of 45164 were excluded because they had prevalent cancer
other than non-melanoma skin cancer at recruitment (n=25184), had incomplete follow-up
data (n=4128), had missing data of diagnosis (n=20), had no lifestyle or dietary information at
recruitment (n=6259), or had an extreme ratio of energy intake to energy requirement (top or
bottom 1%; n=9573); resulting in 476160 participants (70% women) for the present analysis. 
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Identification of pancreatic cancer cases
Pancreatic cancer  incidence was ascertained through population-based cancer  registries  or
active follow-up (Germany, Greece, and France) and confirmed through a mixture of methods
that included health insurance records, and cancer and pathology registries. Participants were
followed until cancer diagnosis, death or last complete follow-up, whichever occurred first.
Fifty seven neuroendocrine PC cases were censored. After a mean follow-up of 14 years, 1283
first incidence PDAC cases were available for analysis, and were classified according to ICD-
Oncology third edition codes C25.0-C25.3 and C25.7-C25.9. 
Information on lifestyle, dietary and nut intake 
Anthropometric measures were assessed at baseline, and participants also answered a lifestyle
questionnaire18.  Country-specific  validated  dietary  questionnaires,  with  the  timeframe
referring to the preceding year,  were used to assess dietary information at baseline 18.  The
determination of nut and seed intake in EPIC has been previously published19,20.  Briefly, the
term ‘nut’ denotes a combination of three terms: tree nuts (including almonds, Brazil nuts,
Cashews,  hazelnuts,  macadamia  nuts,  pecans,  pine  nuts,  pistachios  and  walnuts),  peanuts
(including peanut butter), and non-specific nuts (not specified by the participant). Generally, in
the EPIC cohort, there was a low intake of specific seeds (i.e., sunflower, linseed, pumpkin),
thus ‘seeds’ were combined as a sum total variable. Finally, total intake of nuts and seeds was
used as the main exposure variable (herein referred to as ‘total nut intake’). Consumers were
defined as those who reported an intake >0g per day on average. 
Statistical analysis
Cox proportional hazards models were used to estimate hazards ratio (HR) and 95% confidence
intervals (95%CI) for total nut intake and overall PDAC risk. Total nut intake was analyzed both
as a continuous variable (15g/day; 15g-increments correspond to half a standard serving)21,
and as categorical variable with all non-consumers as the reference category and consumers
categorized in quartiles based on the distribution of total nut intake in the EPIC cohort. All
statistical  models had age as the primary time variable,  were stratified by study center to
control for center effects, and by age at recruitment in 1-year categories. Covariates of gender,
smoking status, diabetes, alcohol consumption, body mass index (BMI), and total energy intake
were included in final models as they were known PC risk factors or potential confounders.
Other  variables  such  as  physical  activity  using  the  Cambridge  index,  education  level,
magnesium (mg/day), red and processed meat, fiber), vegetable,  and fruit intake (all in g/day)
were evaluated but not included as they did not change the HR estimates ≥ 10%. We also
evaluated sex-specific and country-specific categorical variables for total nut intake; however,
since HRs for total nut intake and PDAC risk did not vary from those of the main model, results
were not shown.
Analyses for effect-measure modification were carried out by known PC risk factors: smoking
(never, ever), diabetes (yes, no), and BMI (<25, ≥25 Kg/m2). Heavy alcohol consumption (>60,
0.1-4.9 g/day) was evaluated for men and women combined22. Stratified analyses by sex (male,
female), by geographic region (northern: Norway, Denmark and Sweden; central: Germany,
The Netherlands, the UK and northern of France; southern: southern of France, Italy, Spain and
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Greece), and by country-intake (countries over vs countries below the EPIC median nut intake)
were also investigated.
Sensitivity analyses were performed: 1) Exclusion of PDAC cases that were diagnosed during
the first two years of follow-up to minimize the possible effect of pre-clinical disease on dietary
intake; 2) Restriction to microscopically confirmed PDAC cases (n=910) to reduce a possible
disease  misclassification;  3)  Adjustment  for  the  adapted-relative MED  (arMED)  score
(removing  nuts  from  the  score)23;  4)  Evaluation  of  nut  intake  in  quartiles  of  frequency
(never/almost never, 0.2-1 times/month”, 0.25-≤1 times/week, >1 times/week),  rather than
absolute intake24. This analysis was performed excluding 47171 participants from Cambridge
and Malmö, as frequency data were not available; 5) Removing BMI and diabetes from the
multivariable model; 6) Modeling waist-to-hip ratio (WHR) instead of BMI.
The proportional hazards assumption was evaluated using Schoenfeld residuals,  which was
satisfied in all models. The median value for each category was estimated and included in a
score test to evaluate dose-response trends. The likelihood ratio test (LRT) P-value was used to
evaluate statistical significance of effect-measure modification based on the continuous intake
variable. All  analyses were performed using SAS v.9.3 and STATA v14 was used to test the
proportional hazards assumption. An α-level of 0.05 was used to set the cut-off for statistical
significance. 
RESULTS
Basic information on cohort members. After a mean follow-up of 14 years, 1283 PDAC cases
(57%  women)  were  observed.  More  than  90%  of  the  populations  from  The  Netherlands,
Germany and Greece reported consuming nuts and seeds, whereas only 38.8% of the Spanish
population reported nut/seed consumption. However;  the highest median of intake among
consumers  was  observed  in  Spain  (5.9  g/day),  followed  by  Greece  (5.3  g/day)  and  the
Netherlands (5.0 g/day) (Table 1). Even though the distributions of intake were skewed, means
of intake by country are presented in Table1 to compare to some previously published reports.
Participants classified at the highest levels of total nut intake were more likely to have higher
energy, dietary fiber, vegetable and fruit intakes, whilst non-consumers had higher intakes of
processed meat.  Further,  non-consumers compared to high consumers,  tended to be non-
alcohol drinkers, had higher BMI, and a higher proportion of smokers and were more likely to
report diabetes at baseline (Table2). 
Overall  PDAC risk. No associations and no evidence for  linear  dose-response trends were
observed between total nut intake and PDAC risk in EPIC (highest intake vs non-consumers:
HR:0.89,  95%CI:0.72-1.10,  P-trend:0.70)  (Table3).  The  continuous  total  nut  intake  variable,
assessed  in  15g/day  increments,  was  non-significantly  inversely  associated  (HR15g/day:0.94,
95%CI:0.84-1.07). The three sensitivity analyses performed excluding cases with follow-up <2
years, restricting to microscopically confirmed cases, and adjusting for arMED score, showed
similar  results  (Table3).  Likewise,  when  total  nut  intake  was  analyzed  using  frequency  of
consumption, no statistically significant inverse association was observed (P-trend: 0.23; data
not shown). Results remained unchanged when diabetes and BMI were not included in final
models, and when BMI was replaced by WHR (data not shown). 
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Effect-measure  modification.  No effect-measure modification was observed for  any of  the
stratified analyses according to heavy alcohol consumption, diabetes, smoking status, or BMI
(Table3). There was also no evidence for modification of HRs for total nut intake and PDAC by
sex, geographic region or country-intake (LRT P-value: 0.31, 0.42, and 0.50 respectively; data
not shown). 
DISCUSSION
The present study prospectively assessed the association between total nut intake and PDAC
risk in the EPIC cohort. Although all relative risk (RR) estimates were below the null value, this
study failed to detect  any statistically  significant inverse associations for men and women.
Likewise,  RRs  were  somewhat  lower  when  we  restricted  the  analysis  to  microscopically
confirmed PDAC cases, but no statistically significant associations were observed. Results for
total  nut  intake  and  PDAC  remained  unchanged  when  we  evaluated  effect-measure
modification by various subgroups.
Regular nut consumption has been associated with health benefits in both epidemiological and
clinical  studies.  Regular  nut  consumption  may  play  a  role  in  reducing  insulin  resistance,
inflammation,  hyperglycemia,  and oxidative stress  among others12,24.  Despite  differences  in
nutritional composition by nut subtypes (i.e., walnuts have the highest content in linoleic acid
and  α-linolenic  acid,  hazelnuts  in  fiber,  peanuts  in  protein  and  folate,  pine  nuts  in
polyunsaturated fatty acids), they are considered highly nutritious25. Therefore, nuts have been
postulated as a food group that might have potential in cancer prevention and in lowering
cancer mortality; however, the epidemiologic evidence is still limited, particularly for specific
cancers9–11.
To our knowledge only four published studies have evaluated the potential preventive role of
nut  intake  on  PC  risk,  with  inconclusive  results.  The  first  study  was  conducted  in  the
Netherlands and encompassed 164 PC cases and 480 controls from both genders. The authors
concluded  that  there  was  no  association  between  the  intake  of  “nuts  and  tasty  snacks”
(including peanuts and other nuts, peanut butter, and chips among others) and PC risk 15. The
second study was performed in the prospective Nurses’ Health Study (NHS) of 75680 women,
where the frequency of nut consumption (defined by the sum of peanuts and other nuts) was
statistically significantly inversely associated with PC risk showing an HR of 0.65 (95% CI: 0.47-
0.92;  P-trend=0.007)14. The third study, from the Golestan Cohort Study (GCS; Iran), included
50045 participants and 54 PC cases, and found no association between nut intake and PC risk 17.
The most recent study was conducted in the Netherlands Cohort Study (NLCS) and evaluated
the association between consumption of nuts (sum of peanuts and tree nut), tree nuts, and
peanut butter and the risk of PC overall and by sex. Despite observing lower RRs for higher
consumers compared to non-consumers (HR:0.84, 95%CI:0.63-1.11, P-trend:0.17), none of the
associations or trend tests were statistically significant16. 
Our results  are  consistent  with  those from the case-control  study,  the NLCS and the GCS
studies, but not with the NHS. Nonetheless, we advise caution when comparing results across
studies  since  nut  consumption  was  assessed  differently,  and  the  types  of  nuts  consumed
differed between studies. In EPIC, as discussed by Jenab et al., the exposure variable was a
combination of tree nuts and seeds (≈90% nuts, of which walnuts, almonds and hazelnuts were
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the most regularly consumed )19,20, whereas in both the NHS and the NCLS, peanuts were more
frequently consumed than tree nuts. Similarly, in EPIC-Netherlands, peanuts composed more
than half of total nut and seed intake, but no associations with PDAC were observed in our
investigation  when  country-specific  analyses  were  performed,  including  EPIC-Netherlands.
Nuts and peanuts have different nutritional composition, and thus, they may play different
roles in human health. In the present study we could not analyze them as a unique variable,
but additional studies should try to evaluate these foods items separately. 
Dietary guidelines recommend a minimum portion of 30 g/day of nuts, seeds, and legumes as
they may have beneficial  effects on human health21.  In  the present study,  only 2% of  nut
consumers reported an intake >30 g/day. The general population may have a misconception
about nut consumption, that they are thought to increase weight due to their  high caloric
value; however, in our study, as well as in other published prospective and clinical studies, it
has been observed that high nut consumers have lower BMI and less weight gain compared to
non-consumers24,26. Some studies have suggested a lower risk of type 2 diabetes among nut
consumers as well, although data have not been consistent12. Both excess weight and type-2
diabetes  are  established risk  factors  for  PC;  however,  removing BMI or  diabetes from the
multivariable model, or analyzing waist-to-hip ratio as a measure of abdominal fatness instead
of BMI, did not materially alter our results. 
The present study had the following limitations: although we tried to control for confounding
effects, we could not adjust our models for all known PC risk factors (i.e., family history, ABO
blood group, chronic pancreatitis) because this information was not collected in EPIC. Some
but  not  all  EPIC  dietary  questionnaires  were  designed  to  capture  nut  consumption,  thus,
misclassification of the exposure, and the possibility that some foods that contribute to total
nut intake in EPIC were not assessed (i.e.,  turrón in  Spain) could have also influenced our
results. Further, as mentioned before, specific analyses by type of nut could not be performed,
including for peanut butter. The range of total nut intake in EPIC was narrower than reported
by  the  NLCS  and  the  NHS14,16.  Lastly,  there  is  only  one  dietary  assessment  on  all  EPIC
participants (which was conducted at baseline), thus we were not able to evaluate changes in
diet over time. 
One of the strengths of this study is its prospective design, in which recall bias is less likely than
in case-control  studies,  and EPIC is a multi-country cohort with heterogeneity in diets and
lifestyle factors. We performed a sensitivity analysis excluding cases diagnosed within the first
two years of follow-up to avoid any influence of pre-diagnostic PC on dietary intakes, which
showed similar results to the overall model. Moreover, this is the largest study evaluating the
association between total nut intake and PDAC risk to date (including men and women and
over a thousand of PC cases), which allowed us to evaluate effect measure modification by
several parameters
In  conclusion,  the  results  of  the  present  study  indicate  that  there  were  no  statistically
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